Developer docs
API playgroundTry for free, no card

Search company profiles

Ubix Therapeutics

Full company profile

uuid0002gsi

Namestring
Ubix Therapeutics
Legal namestring
(주)Ubix Therapeutics
Websiteurl
ubixtrx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Ubix Therapeutics is a privately held, Seoul-based biopharmaceutical R&D company founded in June 2018 by CEO BK Seo. The company is built around its proprietary Degraducer® platform, a bifunctional small-molecule technology that recruits disease-related target proteins to E3 ubiquitin ligases via a chemical linker, triggering degradation through the Ubiquitin-Proteasome System (UPS). This targeted protein degradation (TPD) modality is positioned to address targets previously considered undruggable by conventional inhibitors and to overcome drug resistance, with primary therapeutic focus on oncology and immuno-oncology.

Its pipeline includes UBX-303-1, an oral BTK degrader that received US FDA clearance in January 2024 to enter a Phase 1 study in relapsed/refractory B-cell malignancies (CLL, DLBCL); UBX-103, an oral androgen receptor (AR) degrader for metastatic castration-resistant prostate cancer that was out-licensed exclusively worldwide to Yuhan in July 2024; and earlier-stage immuno-oncology candidates UBX-106 and UBX-306 (the latter co-developed with NeoImmuneTech). The company is also advancing Degrader-Antibody Conjugates (DAC) through a 2021 co-research agreement with Debiopharm, and is expanding its owned E3 ligase binder library beyond the canonical CRBN/VHL/IAP set. Core enabling capabilities include medicinal chemistry, structural information analysis, in silico CADD, high-throughput screening, and biological assay infrastructure, much of which is sourced or extended through collaborations with Korean research institutes (KRICT, KRIBB, POSTECH, Gachon University, Kyungpook National University).

Because Ubix has no commercialized products, it generates revenue primarily through upfront payments, research funding, and potential milestones from out-licensing and co-development deals with larger pharmaceutical partners. Its customer base is therefore a small set of pharma counterparties (Yuhan, SK Biopharmaceuticals, Debiopharm, NeoImmuneTech), and its go-to-market is licensing-and-collaboration-led rather than direct sales. The company operates 11–50 employees across a headquarters and Bio Research Center in Songpa-gu, Seoul, and a Chemical Research Center in Yeonsu-gu, Incheon.

Short descriptiontext

Ubix Therapeutics is a Seoul-based clinical-stage biopharmaceutical company developing anti-cancer drugs via its proprietary Degraducer® targeted protein degradation platform, out-licensing and co-developing candidates (BTK, AR, immuno-oncology) with larger pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, anti-cancer therapeutics, bifunctional degraders, oncology drug development, E3 ligase binders
Industry4 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Targeted Protein Degradation Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Royalties
TypeLicensing Royalties
Description

The company generates revenue through exclusive licensing agreements where partners receive worldwide rights for preclinical and clinical development and commercialization of drug candidates. Examples include Yuhan licensing UBX-103 (AR degrader) and NeoImmuneTech licensing T-cell suppressor blockade candidates.

globenewswire.com
2Co-research Collaboration Revenue
TypeProfessional Services
Description

Revenue from research collaboration agreements with pharmaceutical partners such as SK Biopharmaceuticals and Debiopharm, where Ubix provides its Degraducer® platform technology for joint drug development.

ubixtrx.com
3Technology Transfer
TypeLicensing Royalties
Description

Received technological transfer of novel E3 ligase binder technology from KRICT and KRIBB, which forms the foundation of the Degraducer® platform.

ubixtrx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ubix Therapeutics develops novel anti-cancer and immuno-oncology drug candidates based on its proprietary Degraducer® targeted protein degradation platform. The company creates bifunctional small molecules that connect disease-related protein ligands to E3 ubiquitin ligase binders, enabling proteasomal elimination of previously undruggable targets. Its lead asset UBX-303-1 (BTK degrader) received US FDA Phase 1 clearance in January 2024, while UBX-103 (AR degrader) is exclusively licensed to Yuhan, and additional programs (UBX-106, UBX-306, DAC technology) are in research or preclinical stages.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • UBX-303-1 showed excellent PK/PD profiles and superior anti-cancer efficacy in C481S mutant Xenograft mouse model and wild-type models
+2 more records
Product overview1 text field

Ubix Therapeutics is a biopharmaceutical company developing novel anti-cancer drugs based on its proprietary Degraducer® platform technology. The Degraducer® platform enables targeted protein degradation by creating bifunctional molecules that connect disease-related protein ligands to E3 ubiquitin ligase binders, utilizing the body's Ubiquitin-Proteasome System. The company operates a pipeline of therapeutic programs including UBX-303-1 (BTK degrader for hematological cancers in Phase 1), UBX-103 (AR degrader for prostate cancer licensed to Yuhan), and undisclosed immuno-oncology candidates (UBX-106, UBX-306). Ubix is also advancing novel E3 ligase binder research and Degrader-Antibody Conjugates (DAC) technology in partnership with Debiopharm.

Product and service6 records
1Degraducer® Platform Technology
CategoryPlatform Technology
Description

Bifunctional molecule-based targeted protein degradation technology that connects target protein ligands to E3 ubiquitin ligase binders via linkers, enabling elimination of disease-related proteins that were previously undruggable. Used internally for pipeline development and licensed/co-developed with pharmaceutical partners.

2UBX-303-1
CategoryDrug Candidate (Oncology)
Description

A Bruton's tyrosine kinase (BTK) Degrucer designed to degrade over-expressed BTK proteins through a distinct mechanism of action different from current BTK inhibitors, offering advantages in efficacy, resistance overcoming, and selectivity. Targeted at B-cell malignancies including CLL and DLBCL.

3UBX-103
CategoryDrug Candidate (Oncology)
Description

An oral small molecule androgen receptor (AR) degrader for treatment of metastatic castration resistant prostate cancer, licensed exclusively to Yuhan for worldwide development and commercialization.

4UBX-106
CategoryDrug Candidate (Immuno-Oncology)
Description

An undisclosed immuno-oncology drug candidate in research stage, part of Ubix's immuno-oncology pipeline.

5UBX-306
CategoryDrug Candidate (Immuno-Oncology)
Description

An undisclosed immuno-oncology drug candidate developed in collaboration with NeoImmuneTech, in research stage.

6Degrader-Antibody Conjugates (DAC)
CategoryTechnology Platform
Description

A novel drug modality combining Degraducer® molecules with antibody drug conjugates, developed in partnership with Debiopharm using their Multilink™ linker technology for targeted cancer therapy.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-08
Description

Ubix Therapeutics was accepted into the Johnson & Johnson Innovation – JLABS startup incubator program in October 2024, providing access to mentorship, resources, and networking opportunities within the Johnson & Johnson ecosystem.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-07-01
Description

Exclusive license agreement for UBX-103, an oral small molecule AR degrader for treatment of metastatic castration resistant prostate cancer. Yuhan received exclusive worldwide rights for preclinical and clinical development and commercialization.

3SK Biopharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-14
Description

Research collaboration agreement to develop novel anti-cancer therapeutics using Ubix's Degraducer® platform technology and targeted protein degradation (TPD) combined with SK Biopharmaceuticals' drug development capabilities.

ubixtrx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-16
Description

Co-research agreement to develop Antibody Degraducer® Conjugates (ADeC) combining Ubix's Degraducer® molecule with Debiopharm's antibody drug conjugate linker, Multilink™, to specifically target cancer cells.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-03-23
Description

Exclusive License Agreement to develop drug candidates including T-Cell Suppressor Blockades. NeoImmuneTech received rights to advance T-cell related therapeutic candidates.

6KRICT (Korea Research Institute of Chemical Technology)
Strategic tierCoreTypeTechnology or Integration
Description

Received technological transfer of novel E3 ligase binder technology which composes the platform technology Degraducer® from KRICT. Ongoing collaboration to improve and develop Degraducer® applied therapeutics.

ubixtrx.com
7KRIBB (Korea Research Institute of Bioscience and Biotechnology)
Strategic tierCoreTypeTechnology or Integration
Description

Received technological transfer of novel E3 ligase binder technology from KRIBB, forming the foundation of Degraducer® platform. Continuous collaboration to improve and develop Degraducer® applied therapeutics.

ubixtrx.com
8POSTECH
Strategic tierCoreTypeTechnology or Integration
Description

Using POSTECH's proprietary high-throughput screening (HTS) system to discover groundbreaking ligand hits for previously undruggable target proteins, developing first-in-class drugs through utilization of these hits.

ubixtrx.com
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration to secure structural information of target proteins, design new drugs based on the data, and discover diverse E3 ligase binders for the Degraducer® platform.

Strategic tierCoreTypeTechnology or Integration
Description

Research collaborations based on top-level in-silico screening and in-silico modeling technologies for identifying structural characteristics of drug molecules and proteins and optimizing chemical drug candidates.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arvinas is the clinical-stage leader in targeted protein degradation using PROTAC bifunctional molecules. Direct competitor in BTK (ARV-102) and AR degrader programs (ARV-110/bavdegalutamide), validating the same therapeutic strategy Ubix pursues with Degraducer®.

TypeDirect peer
Description

Kymera is a clinical-stage TPD biotech with a Pegasus platform using heterobifunctional degraders. Direct competitor in BTK degrader development (KT-0956) and immuno-oncology, employing a similar protein degradation mechanism to Ubix's Degraducer®.

TypeDirect peer
Description

Nurix is a clinical-stage TPD company with both degrader and molecular glue platforms, working on BTK (NX-2127), BCL6, and other oncology targets. Highly comparable business model of platform-based drug discovery with multiple licensing and partnership transactions.

TypeDirect peer
Description

C4 Therapeutics develops small molecule degraders using its TORPEDO platform for oncology targets. Direct competitor in bifunctional degrader chemistry with multiple programs in hematological malignancies and solid tumors.

TypeDirect peer
Description

Monte Rosa is a clinical-stage biotech developing molecular glue degraders (MGDs) for cancer and inflammatory diseases. Comparable TPD approach targeting previously undruggable proteins, with clinical-stage assets in oncology.

TypeDirect peer
Description

Foghorn is a clinical-stage biotech focused on chromatin biology and protein homeostasis, developing degraders for cancer targets. Comparable oncology-focused protein degradation strategy with platform-based discovery approach.

TypeEmerging player
Description

Amphista is an emerging European TPD company developing next-generation bifunctional degraders with novel mechanisms of action. Comparable protein degradation technology but earlier-stage and more limited pipeline than Ubix.

TypeRegional player
Description

Genexine is a Korean clinical-stage biotech developing biologics and immuno-oncology therapeutics. Regional peer where CEO BK Seo previously served as Head of Business Development, providing direct insight into Korean biotech BD practices.

TypeBroad incumbent
Description

Yuhan is a major Korean pharmaceutical company that licensed UBX-103 from Ubix for worldwide development. Functions as both partner and broader regional incumbent in Korean pharma with established commercialization infrastructure.

10SK Biopharmaceuticals
TypeBroad incumbent
Description

SK Biopharmaceuticals is a Korean pharma company with research collaboration agreement with Ubix (2022). Broader pharmaceutical incumbent providing drug development capabilities for Ubix's TPD programs and serving as a regional comparable.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ubix Therapeutics

Targeted Protein Degradation Therapeuticsubixtrx.com

Ubix Therapeutics is a Seoul-based clinical-stage biopharmaceutical company developing anti-cancer drugs via its proprietary Degraducer® targeted protein degradation platform, out-licensing and co-developing candidates (BTK, AR, immuno-oncology) with larger pharmaceutical partners.

What Ubix Therapeutics does

Ubix Therapeutics is a privately held, Seoul-based biopharmaceutical R&D company founded in June 2018 by CEO BK Seo. The company is built around its proprietary Degraducer® platform, a bifunctional small-molecule technology that recruits disease-related target proteins to E3 ubiquitin ligases via a chemical linker, triggering degradation through the Ubiquitin-Proteasome System (UPS). This targeted protein degradation (TPD) modality is positioned to address targets previously considered undruggable by conventional inhibitors and to overcome drug resistance, with primary therapeutic focus on oncology and immuno-oncology.

Its pipeline includes UBX-303-1, an oral BTK degrader that received US FDA clearance in January 2024 to enter a Phase 1 study in relapsed/refractory B-cell malignancies (CLL, DLBCL); UBX-103, an oral androgen receptor (AR) degrader for metastatic castration-resistant prostate cancer that was out-licensed exclusively worldwide to Yuhan in July 2024; and earlier-stage immuno-oncology candidates UBX-106 and UBX-306 (the latter co-developed with NeoImmuneTech). The company is also advancing Degrader-Antibody Conjugates (DAC) through a 2021 co-research agreement with Debiopharm, and is expanding its owned E3 ligase binder library beyond the canonical CRBN/VHL/IAP set. Core enabling capabilities include medicinal chemistry, structural information analysis, in silico CADD, high-throughput screening, and biological assay infrastructure, much of which is sourced or extended through collaborations with Korean research institutes (KRICT, KRIBB, POSTECH, Gachon University, Kyungpook National University).

Because Ubix has no commercialized products, it generates revenue primarily through upfront payments, research funding, and potential milestones from out-licensing and co-development deals with larger pharmaceutical partners. Its customer base is therefore a small set of pharma counterparties (Yuhan, SK Biopharmaceuticals, Debiopharm, NeoImmuneTech), and its go-to-market is licensing-and-collaboration-led rather than direct sales. The company operates 11–50 employees across a headquarters and Bio Research Center in Songpa-gu, Seoul, and a Chemical Research Center in Yeonsu-gu, Incheon.

Ubix Therapeutics firmographics

Firmographics
Name
Ubix Therapeutics
Legal name
(주)Ubix Therapeutics
Website
https://ubixtrx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Ubix Therapeutics is a Seoul-based clinical-stage biopharmaceutical company developing anti-cancer drugs via its proprietary Degraducer® targeted protein degradation platform, out-licensing and co-developing candidates (BTK, AR, immuno-oncology) with larger pharmaceutical partners.
Ownership category
akta.pro rank

Ubix Therapeutics industry classification

Industry
Product category
Targeted Protein Degradation Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Targeted protein degradation
  • Anti-cancer therapeutics
  • Bifunctional degraders
  • Oncology drug development
  • E3 ligase binders

Where Ubix Therapeutics is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Ubix Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing Royalties: The company generates revenue through exclusive licensing agreements where partners receive worldwide rights for preclinical and clinical development and commercialization of drug candidates. Examples include Yuhan licensing UBX-103 (AR degrader) and NeoImmuneTech licensing T-cell suppressor blockade candidates.
  2. Co-research Collaboration Revenue: Revenue from research collaboration agreements with pharmaceutical partners such as SK Biopharmaceuticals and Debiopharm, where Ubix provides its Degraducer® platform technology for joint drug development.
  3. Technology Transfer: Received technological transfer of novel E3 ligase binder technology from KRICT and KRIBB, which forms the foundation of the Degraducer® platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ubix Therapeutics product offering

Product offering

Core offering

Ubix Therapeutics develops novel anti-cancer and immuno-oncology drug candidates based on its proprietary Degraducer® targeted protein degradation platform. The company creates bifunctional small molecules that connect disease-related protein ligands to E3 ubiquitin ligase binders, enabling proteasomal elimination of previously undruggable targets. Its lead asset UBX-303-1 (BTK degrader) received US FDA Phase 1 clearance in January 2024, while UBX-103 (AR degrader) is exclusively licensed to Yuhan, and additional programs (UBX-106, UBX-306, DAC technology) are in research or preclinical stages.

Product overview

Ubix Therapeutics is a biopharmaceutical company developing novel anti-cancer drugs based on its proprietary Degraducer® platform technology. The Degraducer® platform enables targeted protein degradation by creating bifunctional molecules that connect disease-related protein ligands to E3 ubiquitin ligase binders, utilizing the body's Ubiquitin-Proteasome System. The company operates a pipeline of therapeutic programs including UBX-303-1 (BTK degrader for hematological cancers in Phase 1), UBX-103 (AR degrader for prostate cancer licensed to Yuhan), and undisclosed immuno-oncology candidates (UBX-106, UBX-306). Ubix is also advancing novel E3 ligase binder research and Degrader-Antibody Conjugates (DAC) technology in partnership with Debiopharm.

Differentiator

Problem solved

Functional benefit

Products and services

  • Degraducer® Platform Technology Bifunctional molecule-based targeted protein degradation technology that connects target protein ligands to E3 ubiquitin ligase binders via linkers, enabling elimination of disease-related proteins that were previously undruggable. Used internally for pipeline development and licensed/co-developed with pharmaceutical partners.
  • UBX-303-1 A Bruton's tyrosine kinase (BTK) Degrucer designed to degrade over-expressed BTK proteins through a distinct mechanism of action different from current BTK inhibitors, offering advantages in efficacy, resistance overcoming, and selectivity. Targeted at B-cell malignancies including CLL and DLBCL.
  • UBX-103 An oral small molecule androgen receptor (AR) degrader for treatment of metastatic castration resistant prostate cancer, licensed exclusively to Yuhan for worldwide development and commercialization.
  • UBX-106 An undisclosed immuno-oncology drug candidate in research stage, part of Ubix's immuno-oncology pipeline.
  • UBX-306 An undisclosed immuno-oncology drug candidate developed in collaboration with NeoImmuneTech, in research stage.
  • Degrader-Antibody Conjugates (DAC) A novel drug modality combining Degraducer® molecules with antibody drug conjugates, developed in partnership with Debiopharm using their Multilink™ linker technology for targeted cancer therapy.

Quantifiable outcome

  • UBX-303-1 showed excellent PK/PD profiles and superior anti-cancer efficacy in C481S mutant Xenograft mouse model and wild-type models
  • +2 more outcomes

Companies that use Ubix Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Ubix Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Ubix Therapeutics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and flagship.

  • Johnson & Johnson Innovation – JLABScoreStrategic or Co-development Partner · 8 October 2024Ubix Therapeutics was accepted into the Johnson & Johnson Innovation – JLABS startup incubator program in October 2024, providing access to mentorship, resources, and networking opportunities within the Johnson & Johnson ecosystem.
  • YuhanflagshipOEM/ Whitelabel/ Licensing Partner · 1 July 2024Exclusive license agreement for UBX-103, an oral small molecule AR degrader for treatment of metastatic castration resistant prostate cancer. Yuhan received exclusive worldwide rights for preclinical and clinical development and commercialization.
  • SK BiopharmaceuticalscoreStrategic or Co-development Partner · 14 April 2022Research collaboration agreement to develop novel anti-cancer therapeutics using Ubix's Degraducer® platform technology and targeted protein degradation (TPD) combined with SK Biopharmaceuticals' drug development capabilities.
  • DebiopharmcoreStrategic or Co-development Partner · 16 June 2021Co-research agreement to develop Antibody Degraducer® Conjugates (ADeC) combining Ubix's Degraducer® molecule with Debiopharm's antibody drug conjugate linker, Multilink™, to specifically target cancer cells.
  • NeoImmuneTechcoreOEM/ Whitelabel/ Licensing Partner · 23 March 2020Exclusive License Agreement to develop drug candidates including T-Cell Suppressor Blockades. NeoImmuneTech received rights to advance T-cell related therapeutic candidates.
  • KRICT (Korea Research Institute of Chemical Technology)coreTechnology or IntegrationReceived technological transfer of novel E3 ligase binder technology which composes the platform technology Degraducer® from KRICT. Ongoing collaboration to improve and develop Degraducer® applied therapeutics.
  • KRIBB (Korea Research Institute of Bioscience and Biotechnology)coreTechnology or IntegrationReceived technological transfer of novel E3 ligase binder technology from KRIBB, forming the foundation of Degraducer® platform. Continuous collaboration to improve and develop Degraducer® applied therapeutics.
  • POSTECHcoreTechnology or IntegrationUsing POSTECH's proprietary high-throughput screening (HTS) system to discover groundbreaking ligand hits for previously undruggable target proteins, developing first-in-class drugs through utilization of these hits.
  • Gachon UniversitycoreTechnology or IntegrationCollaboration to secure structural information of target proteins, design new drugs based on the data, and discover diverse E3 ligase binders for the Degraducer® platform.
  • Kyungpook National UniversitycoreTechnology or IntegrationResearch collaborations based on top-level in-silico screening and in-silico modeling technologies for identifying structural characteristics of drug molecules and proteins and optimizing chemical drug candidates.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Ubix Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arvinas: Arvinas is the clinical-stage leader in targeted protein degradation using PROTAC bifunctional molecules. Direct competitor in BTK (ARV-102) and AR degrader programs (ARV-110/bavdegalutamide), validating the same therapeutic strategy Ubix pursues with Degraducer®.
  • Kymera Therapeutics: Kymera is a clinical-stage TPD biotech with a Pegasus platform using heterobifunctional degraders. Direct competitor in BTK degrader development (KT-0956) and immuno-oncology, employing a similar protein degradation mechanism to Ubix's Degraducer®.
  • Nurix Therapeutics: Nurix is a clinical-stage TPD company with both degrader and molecular glue platforms, working on BTK (NX-2127), BCL6, and other oncology targets. Highly comparable business model of platform-based drug discovery with multiple licensing and partnership transactions.
  • C4 Therapeutics: C4 Therapeutics develops small molecule degraders using its TORPEDO platform for oncology targets. Direct competitor in bifunctional degrader chemistry with multiple programs in hematological malignancies and solid tumors.
  • Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing molecular glue degraders (MGDs) for cancer and inflammatory diseases. Comparable TPD approach targeting previously undruggable proteins, with clinical-stage assets in oncology.
  • Foghorn Therapeutics: Foghorn is a clinical-stage biotech focused on chromatin biology and protein homeostasis, developing degraders for cancer targets. Comparable oncology-focused protein degradation strategy with platform-based discovery approach.

Emerging players

  • Amphista Therapeutics: Amphista is an emerging European TPD company developing next-generation bifunctional degraders with novel mechanisms of action. Comparable protein degradation technology but earlier-stage and more limited pipeline than Ubix.

Regional players

  • Genexine: Genexine is a Korean clinical-stage biotech developing biologics and immuno-oncology therapeutics. Regional peer where CEO BK Seo previously served as Head of Business Development, providing direct insight into Korean biotech BD practices.

Broad incumbents

  • Yuhan Corporation: Yuhan is a major Korean pharmaceutical company that licensed UBX-103 from Ubix for worldwide development. Functions as both partner and broader regional incumbent in Korean pharma with established commercialization infrastructure.
  • SK Biopharmaceuticals: SK Biopharmaceuticals is a Korean pharma company with research collaboration agreement with Ubix (2022). Broader pharmaceutical incumbent providing drug development capabilities for Ubix's TPD programs and serving as a regional comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ubix Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ubix Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Ubix Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ubix Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ubix Therapeutics

What does Ubix Therapeutics do?

Ubix Therapeutics develops novel anti-cancer and immuno-oncology drug candidates based on its proprietary Degraducer® targeted protein degradation platform. The company creates bifunctional small molecules that connect disease-related protein ligands to E3 ubiquitin ligase binders, enabling proteasomal elimination of previously undruggable targets. Its lead asset UBX-303-1 (BTK degrader) received US FDA Phase 1 clearance in January 2024, while UBX-103 (AR degrader) is exclusively licensed to Yuhan, and additional programs (UBX-106, UBX-306, DAC technology) are in research or preclinical stages.

Is Ubix Therapeutics a public or private company?

Ubix Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ubix Therapeutics founded?

Ubix Therapeutics was founded in 2018. It employs 1 to 10 people.

Where is Ubix Therapeutics based?

Ubix Therapeutics is headquartered in Seoul, South Korea, in the Asia region.

How does Ubix Therapeutics make money?

Three revenue lines are on record. Licensing Royalties are the primary driver. The others are co-research Collaboration Revenue and technology Transfer.

Who are Ubix Therapeutics's main competitors?

Direct peers on record are Arvinas, Kymera Therapeutics, Nurix Therapeutics, C4 Therapeutics, Monte Rosa Therapeutics and Foghorn Therapeutics. Amphista Therapeutics is listed as an emerging player. Genexine is listed as a regional player. Broad incumbents are Yuhan Corporation and SK Biopharmaceuticals.

Does Ubix Therapeutics have an API?

No public API is recorded for Ubix Therapeutics.

What industry is Ubix Therapeutics in?

Ubix Therapeutics's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireProstate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of AdministrationResearchAndMarkets.com has published the 'Prostate Cancer - Competitive Landscape, 2026' report, covering 230+ companies and 265+ drugs in prostate cancer therapeutics, with key opportunities identified in androgen receptor degraders, radiopharmaceuticals, and immune-targeted therapies. The report highlights significant industry consolidation, including AstraZeneca's acquisition of Fusion Pharmaceuticals for targeted radiopharmaceuticals, AbbVie's purchase of ImmunoGen for ADC-based oncology assets, and Novartis's voluntary takeover offer for MorphoSys to expand its hematology portfolio. Strategic licensing collaborations such as Yuhan's exclusive license for Ubix Therapeutics' preclinical AR degrader program and BeiGene's partnership with Ensem Therapeutics for CDK2 inhibitor development further illustrate the shift toward personalized and precision medicine approaches in prostate cancer treatment.Thebionews‘TPD New Drug Development’ Ubix Therapeutics Successfully Attracts 25.7 Billion Won in Pre-IPO InvestmentUbix Therapeutics raised 25.7 billion won in a pre-IPO round, exceeding its 20 billion won target. The company now has 63 billion won in cumulative investment and plans an IPO targeting the second half of 2025.BioWorldUbix Therapeutics describes new ENL degradation inducersUbix Therapeutics identified proteolysis targeting chimeras (PROTACs) comprising cereblon ligands coupled to an ENL targeting moiety via a linker. The PROTACs are designed to degrade ENL, a protein implicated in cancer.PR NewswireDebiopharm and Ubix Therapeutics Launch Research to Develop a New Anti-Cancer Modality - Antibody Degraducer® ConjugatesDebiopharm, a Swiss-based biopharmaceutical company, and Ubix Therapeutics, a South Korea-based biotech company, announced a co-research agreement on June 16, 2021 to develop a new anti-cancer drug modality called Antibody Degraducer\u00ae Conjugates (ADeC). The collaboration combines Ubix's Degraducer\u00ae molecule technology, which enables selective protein degradation, with Debiopharm's Multilink\u00ae cleavable linker platform, which allows multiple drug payloads to be loaded onto antibodies for enhanced therapeutic effects. The companies aim to achieve pre-clinical proof-of-concept for ADeC, which they believe could improve the efficacy, precision, and safety of antibody-based cancer therapies.